What does UniPharma Co., Ltd. do?

UniPharma Co., Ltd. (6621.TWO) operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. Full company description, peers, and segment breakdown are on the page above.

What is 6621.TWO's market cap?

UniPharma Co., Ltd. (6621.TWO) has a market capitalization of approximately $400.0 million, as of August 27, 2026, based on the most recent share price and shares outstanding.

Does 6621.TWO pay a dividend?

No — UniPharma Co., Ltd. (6621.TWO) does not currently pay a regular dividend. Many growth-stage companies reinvest earnings into the business instead of returning capital to shareholders. The Dividend tab tracks any future declarations.

Is 6621.TWO profitable?

UniPharma Co., Ltd. (6621.TWO) currently reports negative earnings on a trailing-twelve-month basis. The Earnings and Financials tabs show the full EPS history, revenue trend, and analyst forecasts for future profitability.

6621.TWO

UniPharma Co., Ltd.

TWO·Drug Manufacturers, Specialty & Generic · Healthcare

NT$11.10NT$0.00+0.00%

Market capNT$400.02M·Market closed·Aug 27 6:57 AM UTC

Price Chart

NT$11.10+NT$0.00 (+0.00%)today

−5.13%CAGR −1.05%

Select date range

FromTo

Aug 18, 2017Aug 27, 2021 → Aug 27, 2026· 5.0 yrsAug 27, 2026

Key Metrics

6621.TWO does not currently pay a dividend.

EarningsEarnings Tab

EPS (FWD)—

P/E Ratio (FWD)—

EPS Growth (1Y)—

EPS Growth (3Y)—

EPS Growth (5Y)—

Next Earnings Date—

Last Report Date—

Reported vs Estimate—

Earnings Surprise—

FinancialsFinancials Tab

RevenueNT$83.87M

Net Income−NT$40.10M

Net Margin−47.8%

Operating Cash Flow−NT$33.83M

Capital ExpendituresNT$1.16M

Free Cash Flow−NT$34.99M

Return on Equity−20.4%

Return on Invested Capital−11.9%

Net CashNT$95.26M

Value Graph

PRO

See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.

Click below to see what's inside, then upgrade to unlock for 6621.TWO and 80,000+ other tickers.

EPS · Price vs. Fair Value Price Fair

Income Statement Flow

PRO

See exactly how 6621.TWO's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.

The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for 6621.TWO and 80,000+ other tickers.

About UniPharma Co., Ltd.

UniPharma Co., Ltd. is a Taiwanese enterprise specializing in the distribution of pharmaceuticals, medical apparatus, and diagnostic kits. Its diagnostic portfolio encompasses various medical disciplines, including oncology, gynecology, orthopedics, neurology, anesthesiology, and cardiology. The company's offerings feature products such as Adept reduction solution, anesthetic injections (including bain, esmolol HCI, and naloxone), the Elisa DR-70 test for in-vitro tumor detection, and Fomeject antidote injections. Furthermore, UniPharma extends its services to include drug development…

CEO: Jen Chen
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Exchange: TWO
Employees: 34
Website: www.uni-pharma.com

Peers

Peers Tab

7607.TWO

DuoGenic StemCells corporation

Cap

NT$436.2M

4183.TWO

EPS Bio Technology Corp.

Latest News

News Tab

No recent news available.

Frequently Asked Questions About 6621.TWO

What does UniPharma Co., Ltd. do?: UniPharma Co., Ltd. (6621.TWO) operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. Full company description, peers, and segment breakdown are on the page above.
What is 6621.TWO's market cap?: UniPharma Co., Ltd. (6621.TWO) has a market capitalization of approximately $400.0 million, as of August 27, 2026, based on the most recent share price and shares outstanding.
Does 6621.TWO pay a dividend?: No — UniPharma Co., Ltd. (6621.TWO) does not currently pay a regular dividend. Many growth-stage companies reinvest earnings into the business instead of returning capital to shareholders. The Dividend tab tracks any future declarations.
Is 6621.TWO profitable?: UniPharma Co., Ltd. (6621.TWO) currently reports negative earnings on a trailing-twelve-month basis. The Earnings and Financials tabs show the full EPS history, revenue trend, and analyst forecasts for future profitability.